Tiotropium Respimat 2.5microgram solution for inhalation

Indication

COPD

MHRA Drug Safety Update - Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial

Green

Brand:

Spiriva Respimat

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

BNF chapter:

Respiratory system

Background

In line with the Medicines and Healthcare products Regulatory Agency guidance released on the 12^th February 2015, LSCMMG reminds prescribers to review the risk of cardiovascular side effects when prescribing tiotropium (via Respimat or Handihaler) to patients with certain cardiac conditions, who were excluded from clinical trials of tiotropium (including TIOSPIR).

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

COPD Guideline Version 1.9

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Pending	Green	Green	Pending	Green	Green	Green	Pending

What do the colours mean?

Last Updated: 01 - Mar - 2015

Breadcrumb

Tiotropium Respimat 2.5microgram solution for inhalation

Indication

Background

Recommendation

Decisions of Lancashire local decision making groups